Search Results - subject:"Gabapentin"

The Cost Effectiveness of Newer Epilepsy Treatments: A Review of the Literature on Partial-Onset Seizures

Bolin, Kristian; Forsgren, Lars - In: PharmacoEconomics 30 (2012) 10, pp. 903-923

Background and Objective:Background and Objective: Epilepsy is one of the most common neurological disorders, affecting more than 3 million people in Europe. This paper reviews the published evidence regarding the cost effectiveness of second-generation antiepileptic drugs (AEDs). Abstract:...

Persistent link: https://www.econbiz.de/10010569824

A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy

O'Connor, Alec B.; Noyes, Katia; Holloway, Robert G. - In: PharmacoEconomics 26 (2008) 12, pp. 1045-1064

: desipramine 100 mg/day, gabapentin 2400 mg/day, pregabalin 300 mg/day and duloxetine 60 mg/day. Results: Desipramine and … duloxetine were both more effective and less expensive than gabapentin and pregabalin in the base-case analysis and through a …: Desipramine (100 mg/day) and duloxetine (60 mg/day) appear to be more cost effective than gabapentin or pregabalin for treating …

Persistent link: https://www.econbiz.de/10005590367

Cost Effectiveness of Treatments for Amyotrophic Lateral Sclerosis: A Review of the Literature

Ginsberg, Gary; Lowe, Serena - In: PharmacoEconomics 20 (2002) 6, pp. 367-387

Amyotrophic lateral sclerosis (ALS) is a difficult to diagnose, fatal, progressive degenerative disease with an average survival time of 2 to 5 years. Percutaneous endoscopic gastrotomy (PEG) and bi-level intermittent positive pressure (BIPAP) ventilation may be the major interventions leading...

Persistent link: https://www.econbiz.de/10005243201